{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:45:24Z","timestamp":1773110724690,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertension is one of the most prevalent cardiovascular diseases and its treatment requires multimodal therapeutic approaches. This review aims to provide a summary and update on relevant evidence in hypertension research published in 2019\/2020. These include trials dealing with the prognostic effect of systolic and diastolic blood pressure values, the association between hypertension and valve disease, reproducibility of masked and white-coat hypertension, and the prognostic importance of ambulatory and night-time blood pressure measurements. Treatment of hypertension focusing on elderly patients but also the potential cancer risk of thiazide diuretics, the valsartan recall, chronotherapy, and device-based hypertension therapy are discussed.<\/jats:p>","DOI":"10.1038\/s41371-020-00477-1","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:11:47Z","timestamp":1610485907000},"page":"398-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hypertension trials update"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0142-4908","authenticated-orcid":false,"given":"Hussam","family":"Al Ghorani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saarraaken","family":"Kulenthiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Lauder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"477_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317:165\u201382.","journal-title":"JAMA."},{"key":"477_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2018 ESC\/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105\u201387.","journal-title":"J Hypertens."},{"key":"477_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1803180","volume":"381","author":"AC Flint","year":"2019","unstructured":"Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381:243\u201351.","journal-title":"N Engl J Med."},{"key":"477_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American college of cardiology\/American Heart Association task. Hypertension. 2018;71:1269\u2013324.","journal-title":"Hypertension."},{"key":"477_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet."},{"key":"477_CR6","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/eurheartj\/ehy486","volume":"39","author":"K Rahimi","year":"2018","unstructured":"Rahimi K, Mohseni H, Kiran A, Tran J, Nazarzadeh M, Rahimian F, et al. Elevated blood pressure and risk of aortic valve disease: A cohort analysis of 5.4 million UK adults. Eur Heart J. 2018;39:3596\u2013603.","journal-title":"Eur Heart J."},{"key":"477_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jamacardio.2019.2202","volume":"4","author":"M Nazarzadeh","year":"2019","unstructured":"Nazarzadeh M, Pinho-Gomes AC, Smith Byrne K, Canoy D, Raimondi F, Ayala Solares JR, et al. Systolic blood pressure and risk of valvular heart disease: a mendelian randomization study. JAMA Cardiol. 2019;4:788\u201395.","journal-title":"JAMA Cardiol"},{"key":"477_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2019.9811","volume":"322","author":"JA Staessen","year":"2019","unstructured":"Staessen JA, Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322:409\u201320.","journal-title":"JAMA."},{"key":"477_CR9","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","volume":"106","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Pal\u00f9 C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422\u20137.","journal-title":"Circulation."},{"key":"477_CR10","unstructured":"Mancia G, Facchetti R, Cuspidi C, Bombelli M, Corrao G, Grassi G. Limited reproducibility of MUCH and WUCH: evidence from the ELSA study. Eur Heart J. https:\/\/academic.oup.com\/eurheartj\/advance-article-abstract\/doi\/10.1093\/eurheartj\/ehz651\/5572226?redirectedFrom=fulltext."},{"key":"477_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8.","journal-title":"Lancet."},{"key":"477_CR12","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","volume":"389","author":"M B\u00f6hm","year":"2017","unstructured":"B\u00f6hm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226\u201337.","journal-title":"Lancet."},{"key":"477_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","volume":"34","author":"C Thomopoulos","year":"2016","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. J Hypertens. 2016;34:613\u201322. http:\/\/journals.lww.com\/00004872-201604000-00004.","journal-title":"J Hypertens."},{"key":"477_CR14","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/eurheartj\/ehz071","volume":"40","author":"A Douros","year":"2019","unstructured":"Douros A, T\u00f6lle M, Ebert N, Gaedeke J, Huscher D, Kreutz R, et al. Control of blood pressure and risk of mortality in a cohort of older adults: The Berlin Initiative Study. Eur Heart J. 2019;40:2021\u20138.","journal-title":"Eur Heart J."},{"key":"477_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00108-019-0576-9","volume":"60","author":"F Mahfoud","year":"2019","unstructured":"Mahfoud F, B\u00f6hm M, Bongarth CM, Bosch R, Schmieder RE, Schunkert H, et al. Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension. Internist Springe Verl. 2019;60:424\u201330.","journal-title":"Internist Springe Verl"},{"issue":"Nov","key":"477_CR16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet (Lond, Engl) [Internet] 2019;394(Nov):1816\u201326. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31668726.","journal-title":"Lancet (Lond, Engl) [Internet]"},{"key":"477_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","volume":"65","author":"RHGO Engberink","year":"2015","unstructured":"Engberink RHGO, Frenkel WJ, Van Den Bogaard B, Brewster LM, Vogt L, Van Den Born BJH. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis. Hypertension. 2015;65:1033\u201340.","journal-title":"Hypertension."},{"key":"477_CR18","unstructured":"BfArM Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Rote-Hand-Brief zu Hydrochlorothiazid (HCT): Risiko von nichtmelanozyt\u00e4rem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. 2018;1\u20136. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2018\/rhb-hydrochlorothiazid.html."},{"key":"477_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/joim.12629","volume":"282","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282:322\u201331.","journal-title":"J Intern Med."},{"key":"477_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","volume":"78","author":"SA Pedersen","year":"2018","unstructured":"Pedersen SA, Gaist D, Schmidt SAJ, H\u00f6lmich LR, Friis S, Potteg\u00e5rd A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78:673\u2013.e9.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR21","unstructured":"Arzneimittelkommission der Deutschen \u00c4rzteschaft. Hydrochlorothiazid: Risiko von nichtmelanozyt\u00e4rem Hautkrebs \u2013 Empfehlungen der Akd\u00c4 zur Behandlung von Hypertonie und Herzinsuffizienz. 2018;:1\u20137. https:\/\/www.akdae.de\/Stellungnahmen\/Weitere\/20181220.pdf."},{"key":"477_CR22","unstructured":"Liteplo RG, Meek ME, Windle W. Concise International Chemical Assessment Document 38: N-nitrosodimethylamine. IPCS Concise Int Chem Assess Doc. 2002."},{"key":"477_CR23","unstructured":"Grenzwerte f\u00fcr Nitrosamine in Sartanen festgelegt. 2019;116:2019."},{"issue":"Feb","key":"477_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.119.044494","volume":"141","author":"CA Jackevicius","year":"2020","unstructured":"Jackevicius CA, Krumholz HM, Chong A, Koh M, Ozaki AF, Austin PC, et al. Population Impact of Generic Valsartan Recall. Circulation [Internet] 2020;141(Feb):411\u20133. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31707798.","journal-title":"Circulation [Internet]"},{"key":"477_CR25","doi-asserted-by":"crossref","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment a scientific statement from the american heart association professional education committee of the council for high blood pressure research. Circulation. 2008;5:10\u201326.","DOI":"10.1161\/CIRCULATIONAHA.108.189141"},{"key":"477_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet."},{"key":"477_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540\u201350.","journal-title":"Lancet."},{"key":"477_CR28","doi-asserted-by":"crossref","unstructured":"Hermida RC, Crespo JJ, Dom\u00ednguez-Sardi\u00f1a M, Otero A, Moy\u00e1 A, R\u00edos MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2019;754:1\u201312.","DOI":"10.1093\/eurheartj\/ehz754"},{"key":"477_CR29","doi-asserted-by":"publisher","unstructured":"Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. J Hypertens. 2020. https:\/\/doi.org\/10.1097\/HJH.0000000000002479.","DOI":"10.1097\/HJH.0000000000002479"},{"key":"477_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.112.200477","volume":"61","author":"M Rahman","year":"2014","unstructured":"Rahman M, Greene T, Phillips R, Agodoa L, Bakris G, Charleston J, et al. A trial of two strategies to reduce nocturnal blood pressure in african americans with chronic kidney disease. Hypertension. 2014;61:82\u20138.","journal-title":"Hypertension."},{"key":"477_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.110.163014","volume":"57","author":"H Krum","year":"2011","unstructured":"Krum H. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911\u20137.","journal-title":"Hypertension"},{"key":"477_CR32","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903\u20139.","journal-title":"Lancet."},{"key":"477_CR33","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","volume":"65","author":"Z Fang-Fang","year":"2015","unstructured":"Fang-Fang Z, Li-Min Z, Ai-Fang N, Xiao-Ying L, Jing-Rong L, Ke Z, et al. Clinical characteristics of somatic mutations in chinese patients with aldosterone-producing adenoma. Hypertension. 2015;65:622\u20138.","journal-title":"Hypertension."},{"key":"477_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393\u2013401.","journal-title":"N Engl J Med."},{"key":"477_CR35","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;6736:1\u20138.","DOI":"10.1016\/S0140-6736(20)30554-7"},{"issue":"Jun","key":"477_CR36","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391(Jun):2346\u201355.","journal-title":"Lancet"},{"key":"477_CR37","unstructured":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation-EuroIntervention. 2020. https:\/\/eurointervention.pcronline.com\/article\/incidence-of-renal-artery-damage-following-percutaneous-renal-denervation-with-radio-frequency-renal-artery-ablation-systems-review-and-meta-analysis-of-published-reports."}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-00477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-00477-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-020-00477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:24:41Z","timestamp":1684617881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00477-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-00477-1","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Felix Mahfoud and Michael B\u00f6hm are supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), and Deutsche Forschungsgemeinschaft (SFB TRR219), are involved in renal denervation studies and have received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic and ReCor Medical. The other authors do not have conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}